XML 16 R10.htm IDEA: XBRL DOCUMENT

Inventory

6 Months Ended

Jun. 30, 2013

(4)

Inventory

After approval of Vascepa on July 26, 2012 by the FDA, the Company began capitalizing its purchases of saleable inventory of Vascepa. Inventories consist of the following at June 30, 2013 and December 31, 2012 (in thousands):


	June 30, 2013		December 31, 2012
Raw materials	$	5,918	$	5,465
Work in progress		8,491		15,471
Finished goods		13,410		326
Finished goods inventory held by others		695		—

	$	28,514	$	21,262

Inventory is valued at lower of cost or market value, no reserve for excess or obsolete inventory was recorded at either June 30, 2013 or December 31, 2012.

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details